SCHEMBL1636076

SCHEMBL1636076

C#Cc1cccc(C(=O)Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
TSHR P16473 1/20 0.46
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
PTPN1 P18031 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
FFAR1 O14842 1/20 0.41
P2RX1 P51575 1/20 0.40
DRD2 P14416 3/20 0.40
DRD4 P21917 3/20 0.40
DRD3 P35462 3/20 0.40
GSK3B P49841 2/20 0.40
HDAC3 O15379 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3839084 0.83 TDP1 (0.52) ALDH1A1CA12CA1CA2CA9
SCHEMBL256865 0.82 CA12 (0.52) TSHRCA12CA1CA2CA9
SCHEMBL103415 0.82 ALDH1A1 (0.47) ALDH1A1TSHRCA12CA1CA2
SCHEMBL29411053 0.82 CA12 (0.52) TSHRCA12CA1CA2CA9
Hydrochloric Acid SCHEMBL4350304 0.80 CA12 (0.50) TSHRCA12CA1CA2CA9
SCHEMBL1568517 0.80 PARP1 (0.53) TSHRCA12CA1CA2CA9
SCHEMBL31575813 0.80 GSK3B (0.61) ALDH1A1TSHRMEN1KMT2AGSK3B
SCHEMBL10412423 0.80 ALDH1A1 (0.46) ALDH1A1TSHRMEN1KMT2ATDP1
SCHEMBL1636079 0.80 LMNA (0.47) ALDH1A1CA12CA1CA2CA9
SCHEMBL19881259 0.80 CA12 (0.43) CA12CA1CA2CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250257041-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-08-14 US disclosed
EP-4526291-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER The Board of Regents of the University of Texas System (US) 2025-03-26 EP disclosed
WO-2023225327-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-11-23 WO disclosed
US-11407745-B2 Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-08-09 US disclosed
US-20200392127-A1 NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-12-17 US disclosed
US-20150243910-A1 TRANSITION METAL COMPLEXES COMPRISING ASYMMETRIC TETRADENTATE LIGANDS SOLVAY (BE) 2015-08-27 US disclosed
US-20150243910-A1 TRANSITION METAL COMPLEXES COMPRISING ASYMMETRIC TETRADENTATE LIGANDS SOLVAY (BE) 2015-08-27 US disclosed
WO-2014033050-A1 TRANSITION METAL COMPLEXES COMPRISING ASYMMETRIC TETRADENTATE LIGANDS SOLVAY SA (BE) 2014-03-06 WO disclosed
EP-2042506-B1 SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX UBE INDUSTRIES (JP) 2012-12-19 EP disclosed
US-7932398-B2 Substituted phenylethynylgold-nitrogen-containing heterocyclic carbene complex UBE INDUSTRIES, LTD. (JP) 2011-04-26 US disclosed
US-20090234130-A1 SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX UBE INDUSTRIES, LTD. (JP) 2009-09-17 US disclosed
US-20090221779-A1 FILM FORMING COMPOSITION, INSULATING FILM, AND ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2009-09-03 US disclosed
US-20090221779-A1 FILM FORMING COMPOSITION, INSULATING FILM, AND ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2009-09-03 US disclosed
EP-1457511-B1 CROSSLINKABLE AROMATIC RESINS HAVING PROTONIC ACID GROUPS AND ION CONDUCTIVE POLYMER MEMBRANES BINDERS AND FUEL CELLS MADE BY USING THE SAME MITSUI CHEMICALS INC (JP) 2009-07-15 EP disclosed
EP-2042506-A1 SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX Ube Industries, Ltd. (JP) 2009-04-01 EP disclosed
US-7345135-B2 Crosslinkable aromatic resin having protonic acid group, and ion conductive polymer membrane, binder and fuel cell using the resin MITSUI CHEMICALS, INC. (JP) 2008-03-18 US disclosed
US-20040191602-A1 Crosslinkable aromatic resin having protonic acid group, and ion conductive polymer membrane, binder and fuel cell using the resin MITSUI CHEMICALS, INC. (JP) 2004-09-30 US disclosed
EP-1457511-A1 CROSSLINKABLE AROMATIC RESINS HAVING PROTONIC ACID GROUPS AND ION CONDUCTIVE POLYMER MEMBRANES BINDERS AND FUEL CELLS MADE BY USING THE SAME Mitsui Chemicals, Inc. (JP) 2004-09-15 EP disclosed
US-4837256-A SOLVENT RESISTANCE AMOCO CORPORATION (US) 1989-06-06 US disclosed
US-4739089-A Acylation of polysilylaromatic organic compounds and products obtained therefrom GENERAL ELECTRIC COMPANY (US) 1988-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392127-A1 NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME ABL1, DDR1, ABL2 ALDH1A1 1095/4885TSHR 3988/4885CA12 4865/4885
US-20250257041-A1 INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER DDIT3, ATF4, EIF2AK3 ALDH1A1 4205/4885TSHR 4131/4885CA12 4559/4885
US-11407745-B2 Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same ABL1, DDR1, ABL2 ALDH1A1 1028/4885TSHR 3712/4885CA12 4873/4885
US-20090234130-A1 SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX CCRL2, CCNL2, ATXN2L ALDH1A1 3101/4885TSHR 3248/4885CA12 924/4885
US-20090221779-A1 FILM FORMING COMPOSITION, INSULATING FILM, AND ELECTRONIC DEVICE CCNT1, CCNA1, BMI1 ALDH1A1 1449/4885TSHR 3841/4885CA12 263/4885
US-20150243910-A1 TRANSITION METAL COMPLEXES COMPRISING ASYMMETRIC TETRADENTATE LIGANDS AP2M1, AP3M1, AP1M1 ALDH1A1 3225/4885TSHR 2338/4885CA12 827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.